Related Experiment Video

Updated: Aug 14, 2026

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Carbamazepine 10,11-epoxide in children

G W Rylance, C Edwards, P R Gard

    British Journal of Clinical Pharmacology
    |December 1, 1984
    PubMed

    Insights

    Saliva accurately reflects carbamazepine (CBZ) and its metabolite CBZ-epoxide (CBZ-E) levels in children. This finding supports using saliva for therapeutic drug monitoring of CBZ in pediatric patients.

    Area of Science:

    • Pharmacology
    • Clinical Chemistry
    • Pediatric Medicine

    Background:

    • Carbamazepine (CBZ) is a widely used antiepileptic drug in children.
    • Monitoring CBZ and its active metabolite, carbamazepine-10,11-epoxide (CBZ-E), is crucial for therapeutic drug management.
    • Non-invasive methods for drug monitoring are desirable in pediatric populations.

    Purpose of the Study:

    • To investigate the correlation between carbamazepine (CBZ) and its epoxide metabolite (CBZ-E) concentrations in plasma and saliva.
    • To assess the utility of saliva as a non-invasive matrix for therapeutic drug monitoring of CBZ in children.
    • To evaluate the pharmacokinetic profile and contribution of CBZ-E to the overall anticonvulsant effect in pediatric patients.

    Main Methods:

    • Simultaneous collection of plasma and mixed saliva samples from 15 children (aged 1-13 years) treated with carbamazepine.
    • Hourly saliva sampling from six children over dose intervals to analyze CBZ and CBZ-E concentrations.
    • Statistical analysis to determine the correlation between plasma and saliva concentrations and to assess drug fluctuations.

    Main Results:

    • Significant correlations were observed between saliva and plasma concentrations for both CBZ (r=0.91) and CBZ-E (r=0.91).
    • The steady-state CBZ-E/CBZ concentration ratio in saliva was consistently around 0.40 +/- 0.21.
    • Percentage fluctuations in combined CBZ + CBZ-E levels were less pronounced than those of CBZ-E alone, suggesting a stabilizing effect.

    Conclusions:

    • Saliva is a reliable and non-invasive matrix for monitoring carbamazepine (CBZ) and its active metabolite CBZ-epoxide (CBZ-E) in children.
    • The consistent CBZ-E/CBZ ratio in saliva supports its use in assessing drug exposure and potential therapeutic effects.
    • CBZ-E contributes significantly to the overall anticonvulsant activity, potentially up to 30% in children on CBZ monotherapy.

    More Related Videos

    Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

    Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

    Published on: May 16, 2019

    Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

    Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

    Published on: September 20, 2024

    Related Concept Videos

    Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

    Antiepileptic Drugs: GABAergic Pathway Potentiators

    γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
    The key GABA pathway potentiators used in epilepsy management are as follows.
    Benzodiazepines are a well-known class of drugs used for their...
    Antiepileptic Drugs: Calcium Channel Blockers01:17

    Antiepileptic Drugs: Calcium Channel Blockers

    Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
    Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Antiepileptic Drugs: Potassium Channel Activators01:20

    Antiepileptic Drugs: Potassium Channel Activators

    Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
    Ezogabine has gained approval as an adjunctive treatment...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...